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  159 
Abstract 160 
Background: Pediatric asthma remains a public health challenge with enormous impact worldwide.  161 
Objective: The aim of this study was to identify and prioritize unmet clinical needs in pediatric asthma, 162 
that could be used to guide future research and policy activities.  163 
Methods: We first identified unmet needs through an open-question survey administered to 164 
international experts in pediatric asthma who were members of the Pediatric Asthma in Real Life (PeARL) 165 
Think Tank. Prioritization of topics was then achieved through a second, extensive survey with global 166 
reach, of multiple stakeholders (leading experts, researchers, clinicians, patients, policy makers and the 167 
pharmaceutical industry). Differences across responder groups were compared. 168 
Results: 57 unmet clinical need topics identified by international experts were prioritized by 412 169 
participants from 5 continents and 60 countries. Prevention of disease progression and prediction of 170 
future risk, including persistence into adulthood, emerged as the most urgent research questions. 171 
Stratified care, based on biomarkers,  were 172 
also highly rated. The identification of minimum diagnostic criteria in different age groups, cultural 173 
perceptions of asthma and best treatment by age group were priorities for responders from low-middle-174 
income countries. There was good agreement across different stakeholder groups in all domains with 175 
some notable exceptions which highlight the importance of involving the whole range of stakeholders in 176 
formulation of recommendations. 177 
Conclusion: Different stakeholders agree in the majority of research and strategic (e.g. prevention, 178 
personalized approach) priorities for pediatric asthma. Stakeholder diversity is crucial for highlighting 179 
divergent issues that future guidelines should consider.  180 
 181 
Keywords: Asthma, childhood asthma, pediatric asthma, research priorities, diagnosis, assessment, 182 
management, clinical research. 183 
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 195 
Highlights 196 
1. What is already known about this topic? 197 
Our understanding and clinical approach to pediatric asthma remains suboptimal, despite it representing 198 
a major health and socioeconomic burden globally. There is a need of high-quality studies in pediatric 199 
asthma, to improve clinical outcomes. 200 
 201 
2. What does this article add to our knowledge? 202 
In an extensive two-stage survey of multiple, international stakeholders, we identified and prioritized 203 
unmet clinical needs for pediatric asthma. Precision medicine, age-specific recommendations and 204 
prevention were, uniformly agreed, unmet needs in pediatric asthma.  205 
 206 
3. How does this study impact current management guidelines? 207 
The identified priorities highlight domains that need to be urgently addressed in guidelines. Differential 208 
positioning by diverse stakeholders clearly demonstrates the benefit of wide inclusion, but also 209 
restructuring of guidelines to reflect the various needs.  210 
  211 
Background 212 
Asthma affects over 10% of children in Europe and North America1, and is expected to exceed 400 213 
million people by the year 20252,3. In low- and middle-income settings (LMICs), asthma is the commonest 214 
non-communicable disease in children, with a rising prevalence and more severe disease than that 215 
occurring in high income countries4. It poses a major health and socioeconomic burden globally, even 216 
though the associated mortality has significantly decreased over recent decades5,6,7. While undoubtedly 217 
asthma in children and adults have major differences, with diverging mechanisms and triggers, different 218 
diagnostics challenges, outcomes and response to treatments, pediatric asthma is very often approached 219 
as an extension of adult asthma. Characteristically, concepts and recommendations are predominantly 220 
based on data extrapolated from clinical research studies conducted in adults2,8. This is engendered by 221 
a lack of high-quality interventional, but also epidemiological, pathophysiological and immunological 222 
studies evaluating asthma in childhood. Shortage of data results from ethical and regulatory constraints 223 
in conducting research in children and from the relatively lenient criteria for the extension of adult asthma 224 
drug licenses to children9,10. 225 
Pediatric Asthma in Real Life (PeARL), a think tank led by international clinical researchers in Pediatric 226 
Asthma initiated by the Respiratory Effectiveness Group (REG), was developed to address this deficit. It 227 
is an expanding group of experts in pediatric asthma, currently comprising over 40 members from 5 228 
continents and 25 countries, who have extensive relevant track record in research and/or clinical practice 229 
of pediatric asthma. The participation of early career researchers and other stakeholders has also been 230 
encouraged. PeARL has an open members policy and healthcare professionals or researchers with 231 
proven expertise (either academic or clinical) in paediatric asthma are welcome to join. Its vision is to 232 
develop consensus and recommendations that will improve patient care and limit the disease burden, by 233 
capturing and evaluating currently available, clinically relevant evidence, as well as crowdsourcing 234 
international expertise on pediatric asthma. In the long-term, we also aspire to conduct and stimulate 235 
international, collaborative, high-quality clinical research aiming to address the most salient of the 236 
evidence gaps relevant to childhood asthma globally.  237 
We report herein the results of an international multi-stakeholder survey aiming to elicit real-life clinical 238 
challenges in pediatric asthma, including asthma in children of pre-school age, to identify evidence gaps 239 
and unmet clinical needs, and prioritize research and strategic directions, while evaluating the 240 
concordance between different stakeholders. 241 
 242 
Methods 243 
This initiative was inaugurated during a face-to-face meeting of international expert clinicians and 244 
scientists, aiming to discuss clinical challenges and unmet clinical needs in pediatric asthma (London, 245 
UK, October 2017)11. We formed a globally representative core group of leading experts in pediatric 246 
asthma and related areas (the PeARL think tank), who contributed to the design and conduct of this 247 
international survey, which was informed by guidance from the Cochrane Priority Setting Methods 248 
Group12 and published guidance on survey research13. 249 
Firstly, we administered an open-question online survey to 28 members of the core group, which 250 
comprised international experts in pediatric asthma with clinical and research expertise (over 75% of 251 
these members are clinicians evaluating children with asthma in their daily practice, between a hundred 252 
and over 2,000 children per year, in primary, secondary and tertiary care settings; members of this group 253 
also have extensive expertise in clinical and/or translational research, evidence based medicine and the 254 
development of clinical guidelines; they have a mean impact factor of 42.7 and a mean i10 of >100). 255 
They were asked to list important unanswered, clinically relevant questions in each of the following 256 
categories: (i) definition, (ii) natural history, (iii) classification, (iv) diagnosis, (v) assessment, (vi) drug 257 
therapy, (vii) non-drug management, (viii) management of exacerbations, and (ix) other. We reviewed all 258 
responses, resolved duplication, re-grouped and re-wrote all identified unique questions in scientific 259 
English language. We also produced a plain English version, to ensure they would be easily understood 260 
by patients and the pharmaceutical industry stakeholder groups. The core group reviewed the revised 261 
questions and established face validity by confirming that the questions effectively captured the topic 262 
under investigation and there were no confusing or (mis)leading questions.  263 
To prioritize these questions, we launched an extensive, second online survey involving different 264 
stakeholders: (i) Leading experts, defined for the purpose of this survey, as clinical researchers in 265 
pediatric asthma, with an overall h-index of at least 30, who have published more than 20 manuscripts 266 
on pediatric asthma with at least 15 citations each, in Scopus, during the last decade; (ii) Researchers, 267 
(iii) Clinicians treating pediatric asthma, (iv) Patients and their caregivers and (v) Representatives of 268 
policy makers, regulators and the pharmaceutical industry. Group (i) was identified through systematic 269 
searches of Scopus; the other stakeholder categories were self-reported by the respondents of the 270 
survey (detailed description of the dissemination strategy is available in the online repository text).  271 
Respondents had the option to select either a scientific or plain English version of this survey. Both 272 
versions are available in the online repository text.  273 
In this second online survey, participants were invited by email to undertake a prioritization exercise 274 
(SurveyMonkey) in which they were asked to select the most salient unmet needs that could have direct 275 
clinical impact on pediatric asthma. Participants were only allowed to select a prespecified number of 276 
options (table 1). They also had the option to suggest additional questions. All additional questions were 277 
reviewed, recurring questions were presented in the main manuscript and the remaining questions in the 278 
online repository text. We compared responses between different stakeholder groups14 and between 279 
participants residing in different continents or countries with different affluence, as classified by the World 280 
Bank15. Chi-squared and multinomial regression analyses was used to identify between-group 281 
differences.  282 
Participants of both stages of the survey were required to provide a valid e-mail, which was used for 283 
removing duplication.  284 
 285 
Results 286 
Fifty-seven unique, important unanswered clinical questions in pediatric asthma were identified by 26 287 
international experts from 16 countries in 5 continents and prioritized by 412 participants from 60 288 
countries in 5 continents (all but Antarctica, details in figures 1, E1, E2 and the online repository text). 289 
Overall, similar responses were observed in the majority of cases across the different stakeholder 290 
groups, continents and economies, suggesting a convergence in relation to unmet needs (figures 2, 3, 291 
E3, E4 and online repository text). Nevertheless, some significant differences were also noted. Both 292 
similarities and differences are described in detail below. Responses stratified according to the continent 293 
or economy of the country of the respondent are available in the online repository text . 294 
 295 
i. Diagnosis, classification and natural history 296 
The top priorities related to the diagnosis, classification and natural history of pediatric asthma were: 297 
(i) the identification of early risk factors for the development of severe asthma (169 out of 412 298 
respondents, 41%); (ii) the evaluation of the impact of available interventions on long-term disease 299 
progression (162/412, 39% of all respondents); and (iii) the development of clinical indices or tools able 300 
to predict asthma persistence into adulthood (160/412, 39%, figure 2). Responses were similarly 301 
distributed across different stakeholder groups, economies and continents. Notably, patients considered 302 
an important priority the prediction of fixed-airway obstruction later in life. Respondents from LMICs, 303 
mostly from Africa and Asia, prioritized the identification of minimum diagnostic criteria in different age 304 
groups. Participants from LMICs were also interested in the identification of the optimal diagnostic 305 
pathway for each phenotype, while on the contrary, there was a relative lack of interest from the 306 
pharmaceutical industry and organizations on this.  307 
 308 
ii. Assessment and monitoring 309 
The identification and validation of diagnostic, prognostic and therapeutic biomarkers emerged as the 310 
most important priority across all categories, as it was selected by 310 of the 412 participants (75%, 311 
figure 3). While patients/caregivers also prioritized this topic, this was to a significantly lower extent 312 
compared to other groups. Standardization of the methods used to monitor pediatric asthma and the 313 
intervals of follow-up were prioritized by 244 out of 412 participants (59%). Moreover, 218/412 314 
respondents (53%) considered clarification of the role of systematic and airway inflammation monitoring 315 
a priority. Other prioritized topics were age-specific criteria to assess asthma control (168/412, 41%) and 316 
severity (164/412, 39%).  317 
Importantly, patients and their caregivers considered the role of patient reported outcomes of school 318 
monitoring as the highest priorities in this domain. In addition, there was a discrepancy in the prioritization 319 
of standardized monitoring of safety, which was prioritized by a significant proportion of clinicians, 320 
patients and caregivers, but less by researchers, experts and pharmaceutical industry. Safety monitoring 321 
was more frequently prioritized by residents of less affluent countries. 322 
 323 
iii. Drug therapy 324 
Introduction of precision medicine through clinically relevant endotypes, phenotypes and/or 325 
biomarkers (200/412, 49% of the participants) and prevention of airway remodeling (188 of 412 326 
respondents, 46%) emerged as important unaddressed needs (figure 4). Responses from stakeholder 327 
groups were more heterogeneous in this domain. Patients, caregivers and clinicians considered criteria 328 
for stepping-down treatments an important priority, but that was less reflected in the other groups. 329 
Similarly, patients and caregivers considered a priority the development of methods to identify the correct 330 
inhaler device for every child and the standardization of asthma management plans, topics that were not 331 
prioritized by any other group of stakeholders. Participants from LMICs prioritized the need for direct 332 
evidence of efficacy and safety of asthma therapies per age group. 333 
 334 
iv. Non-pharmacological interventions and other questions 335 
The interest in non-pharmacological interventions was varied. The evaluation of the role of food 336 
supplements, probiotics, prebiotics and vitamins in the management of pediatric asthma (190/412, 46%) 337 
was prominent (figure 5).  338 
Other prioritized questions included: (i) the evaluation of potential differences across ethnicities 339 
(180/412 participants, 44%), although patients/caregivers lacked equal interest in this topic; (ii) The 340 
criteria for referral for diagnostic assessment by a specialist (174/412, 42%), which were only prioritized 341 
by respondents residing in more affluent countries; (iii) the development of criteria for referral for allergy 342 
testing (159/412, 38%); and (iv) the evaluation of the prevalence and burden of pediatric asthma 343 
(157/412, 38%).  344 
Finally, people from LMICs prioritized the evaluation of the cultural meaning of asthma in different 345 
communities. The increased number of identified priorities in this domain probably reflects the fact that 346 
participants were allowed to select a higher proportion of the topics compared to the other domains (up 347 
to 3 of 5 responses could be selected).  348 
 349 
v. Additional recurring questions 350 
Participants were encouraged to suggest additional questions that were not included in the 351 
preselected list. Recurring suggestions are presented below, while the remaining suggested topics are 352 
listed in the online repository text. Seven participants highlighted the need for methods to improve the 353 
adherence of children to asthma pharmacotherapy. Three participants suggested the need for more 354 
effective management of acute exacerbations. Three participants highlighted the need to explore 355 
interventions that could improve the quality of indoor and outdoor air. Two respondents highlighted the 356 
need to incorporate the values and preferences of children with asthma and their families in the 357 
development of therapeutic strategies. 358 
 359 
Discussion 360 
In an extensive two-stage survey that reached a wide range of relevant stakeholders, continents and 361 
countries of different income, we identified and prioritized unmet clinical needs for pediatric asthma. Our 362 
findings reveal a general agreement among stakeholders for most statements, which provides an 363 
optimistic message and increases the validity of the prioritized concepts. A clear need for stratified care, 364 
based on biomarkers and clinical phenotypes, but also by age group and demographics has been 365 
confirmed. Disease progression and future risk, including persistence of severity, disease persistence 366 
into adulthood and the development of fixed airway obstruction, emerged as the highest concerns. 367 
Notwithstanding the need for intensification of research efforts in this domain, a key difference between 368 
adult, pediatric patients and caregivers becomes apparent: the hope and expectation of modifying the 369 
natural history of the disease and preventing long-term sequalae, more than addressing current 370 
symptoms and control.  371 
Despite the general agreement in priorities, there were some notable differences across the 372 
stakeholder groups. 373 
the pharmaceutical industry interest. This highlights the 374 
importance of involving the whole range of stakeholders in research, guidelines, practice parameters and 375 
policy design. Caregivers of children with asthma focused more on the safe and correct use of available 376 
medications and devices. Characteristically, they prioritized the development of criteria for stepping down 377 
treatments, methods to monitor the disease at school, to identify the correct inhaler device for every child, 378 
and to optimize the implementation of written or electronic asthma management plans. They also 379 
highlighted the need to further explore the role of patient reported outcomes. These topics, which were 380 
a lower priority for the other groups, clearly reflect everyday challenges for children with asthma and their 381 
caregivers. There is a paucity of data looking into the safety and indications of treatment step-down in 382 
children16 and while poor inhaler technique is a prevalent cause of uncontrolled asthma, there is still 383 
limited evidence on how to successfully improve it17,18. This should serve as a reminder that apart from 384 
the relatively small group of children with severe, difficult-to-control asthma that require novel and 385 
advanced therapeutic approaches, there is an abundance of children with milder asthma that would 386 
benefit from simpler interventions, for which data is still insufficient19. This may also reflect their need for 387 
more information and guidance by physicians towards caregivers. This could be challenging in the limited 388 
time that a pediatrician or general practitioner can devote to a patient during a visit, and may require 389 
different approaches, such as patient groups or community-based education.  390 
Some key differences in priorities for those in LMICS compared to those in high income areas 391 
emerged. Diagnostic challenges and developing diagnostic criteria for children of different ages, cultural 392 
meaning of asthma in different communities, and the need to stratify treatment options by age were 393 
priorities identified mainly by respondents in LMICs. Given the large childhood population in LMICs and 394 
the high prevalence of severe disease in these areas, these should be considered as pressing priorities 395 
by both researchers and guideline makers.  396 
Seven years ago, the European Academy of Allergy and Clinical Immunology (EAACI) in collaboration 397 
with the  (EFA) published a 398 
position paper summarizing research priorities in allergy, which were identified through consensus 399 
among officers of the organisations20. In the same year, the International Primary Care Respiratory Group 400 
(IPCRG) published research priorities identified through an international Delphi survey of primary care 401 
physicians21. Priorities for pediatric asthma included the conduct of age-specific studies, the development 402 
of non-invasive diagnostic tools, interventions towards asthma exacerbations and evaluation of long-term 403 
effects of immunotherapy in children. Our survey reveals that most of these issues still remain 404 
unaddressed.  405 
Several methodologies have been suggested for the prioritization of research topics. Delphi surveys 406 
aiming to reach consensus among the participants are used extensively22. However, group pressure is a 407 
known limitation, which may mask differences across the different stakeholder groups22. Specifically, 408 
differences in the perceived importance of research questions by non-specialists, patients and their 409 
caregivers, who may be more susceptible to group pressure, may be missed23. Another frequently used 410 
approach suggested by the Child Health and Nutrition Research Initiative (CHNRI), suggests that all 411 
identified research questions should be scored against five criteria: (i) answerability, (ii) effectiveness, 412 
(iii) deliverability, (iv) potential for substantial reduction of disease burden and (v) the impact on equity24. 413 
This method aims to prioritize the research questions that are perceived to have the best value for money. 414 
Both methodologies aim to select a limited number of research priorities, selected either on the basis of 415 
consensus or predicted value for money. While this may be useful for regulators or funding agencies 416 
seeking to prioritize projects for funding, our aim was to map the views of different groups in a global 417 
barometer and for this reason we employed a simpler process for prioritization. A potential limitation of 418 
our methodology was that international experts prepared the initial list of topics used in the prioritization 419 
survey, based on their understanding of the relevant literature, current practices and unmet needs. 420 
Nevertheless, all respondents had the opportunity to suggest additional topics in every domain; only a 421 
few additional questions came up, suggesting that saturation was practically reached.  422 
We did not capture potential conflicts of interest of the [>400] respondents to the prioritization exercise, 423 
however, given the large number of respondents from different stakeholder categories, we believe the 424 
integrity of our findings is maintained. Moreover, responses from each stakeholder group are presented 425 
separately in figures 2-5 and notable differences are discussed.  426 
Another potential limitation of our survey was that it was available in scientific and plain English 427 
versions, but was not translated to other languages. Despite the global geographic spread of the 428 
respondents, this could have limited the representation of non-English speaking people.  429 
The major strength of our study is the inclusion and independent evaluation of the responses of 430 
representatives of five different stakeholder groups and sixty countries with different economies around 431 
the world. While clinicians and researchers across Europe and the USA represented the majority of our 432 
sample, we had adequate responses from all responder groups and we were able to compare and 433 
contrast the responses across responder groups, which were overall homogeneous.  434 
Ethical and regulatory constraints in conducting research in children, in combination with the relatively 435 
lenient criteria for extension of adult asthma drug licenses and non-drug treatment interventions to 436 
children, delay gathering of relevant data9,10. However, given the crucial differences in the mechanisms 437 
and treatment requirements of different phenotypes of childhood asthma, compared to adult asthma, 438 
data extrapolated from adult studies cannot optimally support treatment decisions in children. While 439 
conducting research in children can be criticized because it is not always without risks (similar as with 440 
adults), the risks of administering potentially harmful treatments before the benefits have been 441 
established in the relevant target group is not without risks either. Therefore, there is an urgent need to 442 
promote and facilitate clinical research in pediatric asthma globally and produce much-needed, high-443 
quality, objective evidence. Of course, research involving children, which consist a vulnerable population 444 
should be regulated and adhere to good clinical practice guidelines. In parallel, evidence-informed 445 
recommendations focusing on children of different ages, with contributions by a wide range of 446 
stakeholders and considering the described unmet needs, should be developed. The prioritization of 447 
major unmet needs and -more importantly- the identified discrepancies in the perceived priorities among 448 
patients, clinicians and other stakeholders, has crucial clinical implications. More specifically, they 449 
revealed unaddressed needs of children with asthma and their caregivers for more information, guidance, 450 
careful balancing of therapeutic risks and benefits, and -when appropriate- specialist involvement in the 451 
initial diagnosis of childhood asthma. 452 
  453 
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Figure 1: Demographics of the respondents: (a) Continent, (b) Country affluence, according to the 
World Bank, (c) Stakeholder group. 
Figure 2: Number of participants considering a priority each of the unaddressed clinical questions on 
the diagnosis, classification and natural history, by stakeholder category. Prioritized topics appear in bold. 
For each question, the colors of the bars reflect the difference in the response rate of each respondent 
category from the overall median response rate. 
Figure 3: Number of participants considering a priority each of the unaddressed clinical questions on 
assessment and monitoring, by stakeholder category. Prioritized topics appear in bold. For each 
question, the colors of the bars reflect the difference in the response rate of each respondent category 
from the overall median response rate. 
Figure 4: Number of participants considering a priority each of the unaddressed clinical questions on 
drug therapy, by stakeholder category. Prioritized topics appear in bold. For each question, the colors of 
the bars reflect the difference in the response rate of each respondent category from the overall median 
response rate.  
Figure 5: Number of participants considering a priority each of the unaddressed clinical questions on 
non-drug management and other topics, by stakeholder category. Prioritized topics appear in bold. For 
each question, the colors of the bars reflect the difference in the response rate of each respondent 








                                                                                                                                                                  
Table: 




Diagnosis, Classification and Natural History 13 2-5 
Assessment and Monitoring 13 2-6 
Drug Therapy 15 2-6 
Non pharmacological management and other 
questions 
16 2-6 
Table 1: Number of unaddressed clinical questions (topics) that were included in each domain and 
the number of responses that participants were allowed to select. 
 








 
 
 
 

 
 
 
 













